Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 7, 2013, Pages 568-575

  Konrad, Katja ^a   Scheuing, Nicole ^b   Badenhoop, Klaus ^c   Borkenstein, Martin H ^d   Gohlke, Bettina ^e   Schöfl, Christof ^f   Seufert, Jochen ^g   Thon, Angelika ^h   Holl, Reinhard W ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Antihyperglycemic therapy; Co morbidities; Insulin; Metabolic control; Steroid therapy; Weight status

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DIABETIC PATIENT; DOCUMENTATION; FEMALE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGISTER; RETINOPATHY; SCHOOL CHILD;

ANTIHYPERGLYCEMIC THERAPY; CO-MORBIDITIES; INSULIN; METABOLIC CONTROL; STEROID THERAPY; WEIGHT STATUS;

ADOLESCENT; ADULT; AGED; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; REGISTRIES; YOUNG ADULT;

EID: 84884973002     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2429     Document Type: Article

References (30)

1. Laguna TA, Nathan BM, Moran A. Managing diabetes in cystic fibrosis. Diabetes Obes Metab 2010; 12(10): 858-864.
2. Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010; 33(12): 2677-2683.
3. Bismuth E, Laborde K, Taupin P, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008; 152(4): 540-545.
4. Blackman SM, Hsu S, Vanscoy LL, et al. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 2009; 94(4): 1302-1309.
5. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146(5): 681-687.
6. Gottlieb PA, Yu L, Babu S, et al. No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity. Diabetes Care 2012; 35(8): e57.
7. Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33(12): 2697-2708.
8. Hardin DS, Leblanc A, Marshall G, Seilheimer DK. Mechanism of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab 2001; 281: 1022-1028.
9. Rasouli N, Seggelke S, Gibbs J, et al. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol 2012; 6(5): 1038-1044.
10. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 2001; 90(5): 515-519.
11. Bremer AA. The use of insulin in cystic fibrosis-related diabetes: a philosophical difference from the use of insulin in type 1 and type 2 diabetes. Pediatr Diabetes 2012; 47(11): 1039-1041.
12. Konrad K, Thon A, Fritsch M, et al. Comparison of cystic fibrosis related diabetes with type 1 diabetes based on a German/Austrian pediatric diabetes registry. Diabetes Care 2012; 35: 1-8.
13. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009; 27(11): 2121-2158.
14. Rosenbauer J, Dost A, Karges B, et al. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care 2012; 35(1): 80-86.
15. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32(9): 1626-1631.
16. Reinehr T, Holl RW, Roth CL, et al. Insulin resistance in children and adolescents with type 1 diabetes mellitus: relation to obesity. Pediatr Diabetes 2005; 6(1): 5-12.
17. Gordon CM, Anderson EJ, Herlyn K, et al. Nutrient status of adults with cystic fibrosis. J Am Diet Assoc 2007; 107(12): 2114-2119.
18. Godbout A, Hammana I, Potvin S, et al. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab 2008; 34(6 Pt 1): 568-573.
19. Brennan AL, Gyi KM, Wood DM, Hodson ME, Gedes DM, Baker EH. Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis. J Cyst Fibros 2006; 5(1): 27-31.
20. Fischer R, Nährig S, Kappler M, Griese M. Cystic fibrosis care in transition from adolescence to adult age. Internist (Berl) 2009; 50(10): 1213-1214, 1216, 1218-20.
21. American Diabetes Association. Clinical practice recommendations -2010. Diabetes Care 2010; 33(Suppl. 1): S1-S100.
22. Lind-Ayres M, Thomas W, Holme B, Mauer M, Caramori ML, Moran A. Microalbuminuria in patients with cystic fibrosis. Diabetes Care 2011; 34(7): 1526-1528.
23. Van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008; 7(6): 515-519.
24. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006; 29(12): 2660-2663.
25. Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007; 30(5): 1056-1061.
26. Holl RW, Thon A, Bernhard M, et al. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1997; 25(2): 188-193.
27. Rolon MA, Benali K, Munck A, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001; 90(8): 860-867.
28. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 2009; 8(3): 174-178.
29. Moran A, Pekow P, Grover P, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009; 32(10): 1783-1788.
30. Onady GM, Langdon LJ. Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study. BMC Endocr Disord. 2006; 6: 4.